Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

Cancer Research
Werner ScheuerMax Hasmann

Abstract

The human epidermal growth factor receptor (HER) family plays an important role in cell survival and proliferation, and is implicated in oncogenesis. Overexpression of HER2 is associated with aggressive disease and poor prognosis. Trastuzumab is a humanized monoclonal antibody targeting HER2 and has proven survival benefit for women with HER2-positive early and metastatic breast cancer. Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1. We investigated the antitumor activity of these agents alone and in combination in HER2-positive breast and non-small cell lung cancer xenografts. Our data show that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in both xenograft models, something that cannot be achieved by either monotherapy. The enhanced efficacy of the combination was also observed after tumor progression during trastuzumab monotherapy. Near-IR fluorescence imaging experiments confirm that pertuzumab binding to tumors is not impaired by trastuzumab pretreatment. Furthermore, we show by in vi...Continue Reading

References

Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Apr 17, 2001·International Journal of Cancer. Journal International Du Cancer·G CoxK J O'Byrne
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y Yarden
Mar 15, 2002·Seminars in Oncology·Fred R HirschPaul A Bunn
Mar 22, 2002·Nature·Yotaro IzumiRakesh K Jain
Nov 25, 2003·The Annals of Pharmacotherapy·Marcus Ferrone, Susannah E Motl
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U GatzemeierV Hirsh
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amir OnnRoy S Herbst
Feb 6, 2004·Molecular & Cellular Proteomics : MCP·Jeffrey S RossGabriel N Hortobagyi
Apr 20, 2004·Cancer Cell·Matthew C FranklinMark X Sliwkowski
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Hadi YazijiAllen M Gown
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TannerJ Isola
Apr 20, 2005·Cancer Cell·Stevan R Hubbard
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas FriessMax Hasmann
Sep 10, 2005·Cancer Immunology, Immunotherapy : CII·Camellia W AdamsMark X Sliwkowski
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 7, 2006·Cancer Letters·Rita Nahta, Francisco J Esteva
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Jul 4, 2008·Annals of the New York Academy of Sciences·Simone Diermeier-DaucherGero Brockhoff

❮ Previous
Next ❯

Citations

Oct 1, 2011·Breast Cancer Research and Treatment·Eugene R Ahn, Charles L Vogel
Jun 14, 2012·Clinical & Experimental Metastasis·Alison T StopeckHope S Rugo
Feb 5, 2013·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Ricardo H Alvarez, Gabriel N Hortobagyi
Jul 25, 2013·Advances in Therapy·Leticia De Mattos-Arruda, Javier Cortes
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Jan 30, 2013·Nature Reviews. Clinical Oncology·Sook Ryun ParkShivaani Kummar
Jun 8, 2011·Nature Reviews. Gastroenterology & Hepatology·Lorenzo FornaroAlfredo Falcone
Apr 24, 2010·Nature Reviews. Immunology·Louis M WeinerShangzi Wang
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Aug 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Charles EigenbrotTorleif Härd
Aug 2, 2012·Proceedings of the National Academy of Sciences of the United States of America·Mark X Sliwkowski
Sep 5, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ruth MaronMichael Sela
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Baselga
Jun 15, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LenihanJ Baselga
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M CapelanM J Piccart-Gebhart
May 24, 2011·International Immunology·Esther J WitschMichael Sela
Jul 25, 2012·Anti-cancer Drugs·Conleth G Murphy, Patrick G Morris
Dec 18, 2012·Current Opinion in Obstetrics & Gynecology·Gottfried E Konecny
Mar 31, 2012·Science Translational Medicine·Howard M Stern
Jan 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vandana Abramson, Carlos L Arteaga
Dec 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joan T GarrettCarlos L Arteaga
Oct 4, 2011·The Journal of Clinical Investigation·Michaela J Higgins, José Baselga
Oct 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kaori Fujimoto-Ouchi
Jan 21, 2014·Current Oncology Reports·Sara Tolaney
Dec 11, 2013·Current Treatment Options in Oncology·Ishwaria M Subbiah, Ana Maria Gonzalez-Angulo
Dec 20, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R BartschUNKNOWN Biotherapy Development Association (BDA)
May 28, 2014·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Alessandra FabiOreste Segatto
May 29, 2013·Pharmacology & Therapeutics·Geniey YangAlexandros G Georgakilas
Jul 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W J Gradishar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.